DalCor Pharmaceuticals is developing dalcetrapib, the first pharmacogenetic precision medicine targeting patients with the AA genotype at the rs1967309 location in the ADCY9 gene, to reduce the risk of fatal and non-fatal myocardial infarction following acute coronary syndrome. The ongoing Dal-GenE-2 Phase 3 trial aims to confirm a 21% relative risk reduction in cardiovascular events for this specific genetic subset.

Glycomine is developing GLM101, a mannose-1-phosphate replacement therapy currently in clinical trials for PMM2-CDG, a rare genetic disease caused by glycosylation defects. This therapy aims to restore the missing biochemical function, offering potential disease modification rather than merely symptomatic relief.

InterMune discovers and advances small‑molecule inhibitors and monoclonal antibodies that block key profibrotic pathways such as TGF‑β and PDGF to treat idiopathic pulmonary fibrosis and other lung fibrotic diseases. The company integrates companion‑diagnostic biomarkers for patient stratification and employs adaptive Phase II/III trials to accelerate regulatory approval, generating revenue from product sales and licensing royalties.

Metavention provides a minimally invasive renal (and hepatic) denervation procedure using its proprietary iRF Denervation System, which delivers radio‑frequency energy with integrated cooling to permanently disrupt overactive sympathetic nerves. The one‑time outpatient treatment aims to lower blood pressure and improve metabolic parameters in patients with resistant hypertension or uncontrolled type 2 diabetes, offering an alternative to additional medication.